Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

News SummaryMost relevantAll newsSector newsTweets

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
01/26/2013 | 08:35pm CEST

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
[email protected]

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
09/21 IONIS PHARMACEUTICALS : Patent Issued for Method for Solution Phase Detritylatio..
09/21 IONIS PHARMACEUTICALS : New Data Presented at European Society for Medical Oncol..
09/13 IONIS PHARMACEUTICALS INC. : - Antitumor Activity with IONIS STAT3 2.5 Rx in Com..
09/13 AKCEA THERAPEUTICS : Announces Filing of New Drug Submission for Volanesorsen to..
09/11 IONIS PHARMACEUTICALS : New Data Presented at European Society for Medical Oncol..
09/07 IONIS PHARMACEUTICALS : Earns $40 Million SPINRAZA Regulatory Milestone Payment ..
09/07 AKCEA THERAPEUTICS : Establishes Canadian Subsidiary
09/06 AKCEA THERAPEUTICS : Ionis spinout Akcea files for approval of volanesorsen
09/01 IONIS PHARMACEUTICALS : Earns $40 Million SPINRAZA Regulatory Milestone Payment ..
09/01 AKCEA THERAPEUTICS : and Ionis Announce Submission of New Drug Application for V..
More news
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Financials ($)
Sales 2017 435 M
EBIT 2017 14,5 M
Net income 2017 -25,1 M
Finance 2017 223 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 4 546,49
EV / Sales 2017 14,3x
EV / Sales 2018 12,9x
Capitalization 6 445 M
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 14
Average target price 56,3 $
Spread / Average Target 8,6%
EPS Revisions
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Inside Director
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Joseph H. Wender Independent Outside Director
Frederick T. Muto Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP57.01%19 853
CELLTRION, INC.--.--%15 738